Explore

Trendline Trendline
Sanofi Abandons Two R Programs Amid Pipeline Revamp

Sanofi Abandons Two R Programs Amid Pipeline Revamp

Sanofi Abandons Two R Programs Amid Pipeline Revamp
Reuters Reuters
Regeneron beats quarterly estimates on eczema drug strength, shares rise

Regeneron beats quarterly estimates on eczema drug strength, shares rise

July 30 (Reuters) - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Shares rose nearly 5% before the bell.
Trendline Trendline
Incyte Reports 38% Revenue Increase in Q2 2026, Updates Financial Guidance

Incyte Reports 38% Revenue Increase in Q2 2026, Updates Financial Guidance

Incyte Reports 38% Revenue Increase in Q2 2026, Updates Financial Guidance
Trendline Trendline
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding
Trendline Trendline
Agenus to Announce Q2 2026 Financial Results and Development Update

Agenus to Announce Q2 2026 Financial Results and Development Update

Agenus to Announce Q2 2026 Financial Results and Development Update
Trendline Trendline
Aker BioMarine's Takeover Offer Receives Significant Shareholder Support

Aker BioMarine's Takeover Offer Receives Significant Shareholder Support

Aker BioMarine's Takeover Offer Receives Significant Shareholder Support
Trendline Trendline
Novartis Seeks Clinical Research Associate Manager to Enhance Trial Operations

Novartis Seeks Clinical Research Associate Manager to Enhance Trial Operations

Novartis Seeks Clinical Research Associate Manager to Enhance Trial Operations
Trendline Trendline
Alkermes Reports Strong Financial Results for Q2 2026 Amidst Neuroscience Innovations

Alkermes Reports Strong Financial Results for Q2 2026 Amidst Neuroscience Innovations

Alkermes Reports Strong Financial Results for Q2 2026 Amidst Neuroscience Innovations
Trendline Trendline
Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets
Reuters Reuters
GSK launches $2.5 billion savings drive to fund faster drug development

GSK launches $2.5 billion savings drive to fund faster drug development

By Bhanvi Satija and Raechel Thankam Job LONDON, July 28 (Reuters) - GSK launched a £1.9 billion ($2.52 billion) cost-savings effort on Tuesday to help fund the British drugmaker's expanded late-stage study roster, as CEO Luke Miels works to deliver on his promise of faster drug development.
Trendline Trendline
MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline

MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline

MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline
Trendline Trendline
Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments